Skip to content

Dr. Gearóid Tuohy

Clinical distinctions between EYS- and USH2A-associated Retinitis Pigmentosa (RP) provides important implications for diagnosis, counselling and clinical practice.

Researchers based at the Singapore National Eye Centre, and the Ophthalmology and Visual Sciences, Duke-NUS Graduate Medical School, Singapore, have published a report showing clear… Read More »Clinical distinctions between EYS- and USH2A-associated Retinitis Pigmentosa (RP) provides important implications for diagnosis, counselling and clinical practice.

Encapsulated cell therapy from Neurotech Pharmaceuticals has reported FDA approval for the treatment for MacTel (Macular Telangiectasia Type 2).

Neurotech Pharmaceutics, Inc., a private clinical stage biotech company based in Cumberland, Rhode Island, US, has announcedthat the Food and Drug Administration (FDA) has approved… Read More »Encapsulated cell therapy from Neurotech Pharmaceuticals has reported FDA approval for the treatment for MacTel (Macular Telangiectasia Type 2).

New research on retinal organoids provide valuable insights on genotype and phenotype correlations in Stargardt disease (STGD1).  

Researchers at the Biosciences Institute, Newcastle University, UK, have reported results from a study on differentiated retinal organoids derived from Stargardt disease patients (STGD1). The… Read More »New research on retinal organoids provide valuable insights on genotype and phenotype correlations in Stargardt disease (STGD1).  

Final efficacy and safety results for the conclusion of a Phase III trial with LUMEVOQ (GS010; lenadogene nolparvovec) reports visual acuity improvement for ND4-LHON patients.

The outcomes of an experimental treatment of “LUMEVOQ” (GS010; lenadogene nolparvovec), for ND4-LHON patients, were presented this month by GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985,… Read More »Final efficacy and safety results for the conclusion of a Phase III trial with LUMEVOQ (GS010; lenadogene nolparvovec) reports visual acuity improvement for ND4-LHON patients.

Research on autosomal dominant retinitis pigmentosa (adRP) has reported a novel RP1 truncating mutation, not previously reported in the literature.  

Researchers at the Eye Centre, Zhejiang University School of Medicine, Hangzhou, China, have reported a novel truncating mutation in the RP1 gene (retinitis pigmentosa 1),… Read More »Research on autosomal dominant retinitis pigmentosa (adRP) has reported a novel RP1 truncating mutation, not previously reported in the literature.  

Foundation Fighting Blindness (FFB) have presented genetic data on IRDs for almost 34,000 patients and families within international sites.

A collaboration of 41 international clinical centres that manage patients affected with inherited retinal diseases (IRDs), supported by the US Foundation Fighting Blindness (FFB), have… Read More »Foundation Fighting Blindness (FFB) have presented genetic data on IRDs for almost 34,000 patients and families within international sites.